Healthcare resource use in hospitalized patients with carbapenem-resistant Gram-negative infections

Xu, 2017, Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae, Ann Clin Microbiol Antimicrob, 16, 18, 10.1186/s12941-017-0191-3 Touat, 2019, A payer perspective of the hospital inpatient additional care costs of antimicrobial resistance in France: A matched case-control study, Appl Health Econ Health Policy, 17, 381, 10.1007/s40258-018-0451-1 World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery and development of new antibiotics. Available at: https://Www.Who.Int/medicines/publications/who-ppl-short_summary_25feb-et_ NM_WHO.Pdf [last accessed Sept 2020]. 2013 Haugnes, 2020, Financial and temporal costs of patient isolation in Norwegian hospitals, J Hosp Infect, 104, 269, 10.1016/j.jhin.2019.11.012 Coast, 1996, Superbugs: Should antimicrobial resistance be included as a cost in economic evaluation?, Health Econ, 5, 217, 10.1002/(SICI)1099-1050(199605)5:3<217::AID-HEC200>3.0.CO;2-S Wozniak, 2019, Using the best available data to estimate the cost of antimicrobial resistance: a systematic review, Antimicrob Resist Infect Control, 8, 26, 10.1186/s13756-019-0472-z Thaden, 2017, Increased costs associated with bloodstream infections caused by multidrug-resistant Gram-negative bacteria are due primarily to patients with hospital-acquired infections, Antimicrob Agents Chemother, 61, e01709, 10.1128/AAC.01709-16 Rodriguez-Acevedo, 2020, Hospitalization costs for patients colonized with carbapenemase-producing Enterobacterales during an Australian outbreak, J Hosp Infect, 105, 146, 10.1016/j.jhin.2020.03.009 Otter, 2017, Counting the cost of an outbreak of carbapenemase-producing enterobacteriaceae: An economic evaluation from a hospital perspective, Clin Microbiol Infect, 23, 188, 10.1016/j.cmi.2016.10.005 Bartsch, 2017, Potential economic burden of carbapenem-resistant enterobacteriaceae (CRE) in the United States, Clin Microbiol Infect, 23, 10.1016/j.cmi.2016.09.003 Huang, 2018, In-hospital medical costs of infections caused by carbapenem-resistant klebsiella pneumoniae, Clin Infect Dis, 67, S225, 10.1093/cid/ciy642 Tresman, 2018, Healthcare resource use and attributable cost of clostridium difficile infection: A micro-costing analysis comparing first and recurrent episodes, J Antimicrob Chemother, 73, 2851, 10.1093/jac/dky250 Barnett, 2011, The time-dependent bias and its effect on extra length of stay due to nosocomial infection, Value Health, 14, 381, 10.1016/j.jval.2010.09.008 Melzer, 2007, Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. Coli compared to non-ESBL producing E. Coli, J Infect, 55, 254 Goldenberg, 2012, Clinical negligence, litigation and healthcare-associated infections, J Hosp Infect, 81, 156, 10.1016/j.jhin.2012.04.020 Gordon, 2020, Estimating the value of new antimicrobials in the context of antimicrobial resistance: development and application of a dynamic disease transmission model, Pharmacoeconomics, 38, 857, 10.1007/s40273-020-00906-6